HTG Announces Distribution Agreements with Gamidor and Durviz
News Apr 13, 2016
HTG Molecular Diagnostics, Inc. has announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products.
“By expanding our distribution reach into these markets, we believe the availability of the HTG Edge Seq system and assays will accelerate the adoption of molecular profiling using NGS,” stated Jean Claude Gerard, PhD, VP European Commercial Operations for HTG Molecular Diagnostics. Dr. Gerard added, “Both Gamidor and Durviz are as passionate as we are at HTG about enabling precision medicine at the local level.”
Gamidor provides systems, chemicals, reagents and services in Israel, offering diagnostic solutions to hospitals, health management systems and academic research institutes. Durviz is a distributor of next-generation sequencing reagents and library preparation systems in Spain and Portugal.
“These agreements serve to expand HTG's reach outside the United States and we see our agreements with Gamidor and Durviz as models for additional agreements with distributors in select global markets,” stated TJ Johnson, President and CEO of HTG Molecular Diagnostics.
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.
For centuries, gardeners have attempted to breed blue roses with no success. But now, thanks to modern biotechnology, the elusive blue rose may finally be attainable. Researchers have found a way to express pigment-producing enzymes from bacteria in the petals of a white rose, tinting the flowers blue.
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019
2nd World Congress on Genetics & Genetic Disorders
May 13 - May 14, 2019